You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 131 No. 12, December 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  Studies
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Dermatomyositis Without Muscle Weakness

Long-term Follow-up of 12 Patients Without Systemic Corticosteroids

Anne Cosnes, MD; Florence Amaudric, MD; Romain Gherardi, MD; Josette Verroust, MD; Janine Wechsler, MD; Jean Revuz, MD; Jean Claude Roujeau, MD

Arch Dermatol. 1995;131(12):1381-1385.


Abstract

Background and Design
We retrospectively studied 12 patients with dermatomyositis (DM) with at least one laboratory criterion of muscle involvement but without muscle weakness. We reported their outcome without systemic corticosteroid treatment and searched for distinctive baseline data and associated neoplasia among a group of 29 patients with classic DM.

Results
After a mean follow-up of 5.3 years, complete or partial skin improvement occurred in nine patients with DM without muscle weakness, and muscle enzyme levels were normalized in all. When compared with the classic DM group, no statistical differences were found for associated neoplasia or for any baseline data studied except, as expected, for muscle parameters.

Conclusions
The lack of distinctive baseline data between DM without muscle weakness and classic DM suggests that there is a continuum from amyopathic to classic DM. However, DM without muscle weakness is a clinical entity with respect to favorable long-term prognosis. Unless frank muscle weakness develops, treatment with systemic corticosteroids can be avoided.

(Arch Dermatol. 1995;131:1381-1385)



Author Affiliations

From the Departments of Dermatology (Drs Cosnes, Amaudric, Revuz, and Roujeau), Pathology (Drs Gherardi and Wechsler), and Neurophysiology (Dr Verroust), Hôpital Henri Mondor, Créteil, France.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Muscle Satellite Cells and Endothelial Cells: Close Neighbors and Privileged Partners
Christov et al.
Mol. Biol. Cell 2007;18:1397-1409.
ABSTRACT | FULL TEXT  

STIR Magnetic Resonance Imaging: A Noninvasive Method for Detection and Follow-up of Dermatomyositis
Yosipovitch et al.
Arch Dermatol 1999;135:721-723.
FULL TEXT  

Juvenile Dermatomyositis Presenting With Rash Alone
Eisenstein et al.
Pediatrics 1997;100:391-391.
FULL TEXT  

Amyopathic Dermatomyositis
Kagen
Arch Dermatol 1995;131:1458-1459.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.